Table 1. Cell cycle progression of resting primary human B lymphocytes after transduction with targeted vectors.1.
| Donor 1 | Donor 2 | Donor 3 | Donor 4 | |||||||||
| G1bcells [%] | GFP+cells [%] | MOI | G1bcells [%] | GFP+cells [%] | MOI | G1bcells [%] | GFP+cells [%] | MOI | G1bcells [%] | GFP+cells [%] | MOI | |
| CD20-LV | 36.2 | 13.5 | 3 | 5.9 | 7.4 | 2 | 9.0 | 38.0 | 2 | 10.0 | 59.0 | 2 |
| CD19ds-LV | 9.6 | 4.9 | 3 | 5.1 | 25.8 | 2 | 2.8 | 16.0 | 2 | n.d.5 | n.d. | n.d. |
| MV-LV | 1.1 | 11.8 | 5 | 2.0 | 46.4 | 5 | 0.9 | 35.0 | 2 | 0.0 | 40.0 | 10 |
| untransduced2 | 0.8 | n.a.4 | n.a. | 1.6 | n.a. | n.a. | 0.8 | n.a. | n.a. | 1.0 | n.a. | n.a. |
| untransduced3 | 37.0 | n.a. | n.a. | 14.6 | n.a. | n.a. | 49.0 | n.a. | n.a. | 10.0 | n.a. | n.a. |
1
Cells were analyzed 48 h after transduction.
2
Unstimulated B lymphocytes were analyzed.
3
B lymphocytes were stimulated for 48 h with a cytokine cocktail consisting of 50 ng/ml IL-2, 300 ng/ml CD40Ligand, 10 ng/ml IL-4 and 10 ng/ml IL-10.
4
not applicable.
5
not done.